REDWOOD CITY, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) — Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 1, 2015, the compensation committee of the company’s board of directors granted 14 new employees options to purchase an aggregate of 80,800 shares of the company’s common stock with a per share exercise price of $22.54, the closing trading price on the grant date, and 12,700 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company’s lead product candidate is Patiromer for Oral Suspension for the treatment of hyperkalemia, a potentially life-threatening condition defined as abnormally elevated levels of potassium in the blood. A two-part pivotal Phase 3 trial of Patiromer for Oral Suspension has been completed and the primary and secondary endpoints were met. A New Drug Application for Patiromer for Oral Suspension for the treatment of hyperkalemia was accepted by the U.S. Food and Drug Administration and is currently under review. Patiromer for Oral Suspension has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
CONTACT: Charlotte Arnold Vice President, Corporate Communications 650.421.9352 IR@relypsa.com